Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Bijuva® in Canada

GlobeNewswire November 26, 2019

Profound Medical Announces Health Canada Approval of TULSA-PRO®

GlobeNewswire November 25, 2019

GUD Medison Resolved

GlobeNewswire November 21, 2019

Knight Therapeutics Reports Third Quarter 2019 Results

GlobeNewswire November 12, 2019

Notice of Knight Therapeutics' Third Quarter 2019 Results Conference Call

GlobeNewswire November 5, 2019

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta(TM) in Canada

Business Wire October 30, 2019

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta(TM) in Canada

GlobeNewswire October 30, 2019

Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX(TM) in Canada

GlobeNewswire October 23, 2019

Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform

GlobeNewswire October 21, 2019

Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets

Business Wire September 3, 2019

Israeli Courts Rule Against Knight Therapeutics' and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison

Business Wire August 26, 2019

Medison Expresses Concerns over Knight Therapeutics' Second Quarter Results and Demands Answers to Critical Questions from Jonathan Goodman

Canada NewsWire August 9, 2019

Knight Therapeutics Reports Second Quarter 2019 Results

GlobeNewswire August 8, 2019

Knight Announces Early Warning Filing Regarding Disposition of Shares of Crescita

GlobeNewswire August 6, 2019

Knight Therapeutics and pan-Canadian Pharmaceutical Alliance (pCPA) Reach Agreement for PROBUPHINE® for Opioid Dependence

GlobeNewswire August 6, 2019

Notice of Knight Therapeutics' Second Quarter 2019 Results Conference Call

GlobeNewswire August 1, 2019

Medison Biotech Considers Requisition of Special Meeting of Shareholders of Knight Therapeutics Inc.

Business Wire July 18, 2019

Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer

GlobeNewswire July 16, 2019

Medison Biotech: Jonathan Goodman Takes Advantage of His Own Failure to Create Value, Enriching Himself at the Expense of the Shareholders of Knight Therapeutics

Business Wire July 9, 2019

Knight Announces Normal Course Issuer Bid

GlobeNewswire July 8, 2019